# BRINSUPRI® (brensocatib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/brensocatib

> The FDA approved BRINSUPRI® (brensocatib), sponsored by INSMED Inc (INSM), on August 12, 2025 for to treat non-cystic fibrosis bronchiectasis.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is BRINSUPRI® (brensocatib) FDA approved?

Yes. The FDA approved BRINSUPRI® (brensocatib), sponsored by INSMED Inc (INSM), on August 12, 2025 for to treat non-cystic fibrosis bronchiectasis. FDA novel drug approvals: "Brinsupri | brensocatib | 8/12/2025 | To treat non-cystic fibrosis bronchiectasisDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/brensocatib)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/brensocatib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | BRINSUPRI® (brensocatib) |
| Codes | INS1007 |
| Sponsor | INSMED Inc (INSM) https://sec-api.dev/companies/insm/catalysts |
| Indications | [crssnp](https://sec-api.dev/indications/crssnp), [bronchiectasis](https://sec-api.dev/indications/bronchiectasis), non-cystic fibrosis bronchiectasis, [chronic rhinosinusitis without nasal polyps](https://sec-api.dev/indications/chronic-rhinosinusitis-without-nasal-polyps), bronchiectasis remains, To treat non-cystic fibrosis bronchiectasis, [Hidradenitis Suppurativa](https://sec-api.dev/indications/hidradenitis-suppurativa) |
| Modality |  |
| FDA designations | breakthrough, orphan, priority review |

## Timeline

### Dec 2024: NDA/BLA submission

- Status: completed. Date confidence: month. Indication: bronchiectasis with the U.
- First seen 2025-01-10, last confirmed 2025-01-10.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-000711): "Insmed submitted a new drug application (NDA) for brensocatib for patients with bronchiectasis with the U.S. Food and Drug Administration (FDA) in December 2024 and is currently awaiting FDA acceptance of that submission." https://www.sec.gov/Archives/edgar/data/1104506/000114036125000711/ef20041296_ex99-1.htm

### Dec 2024: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-02-20, last confirmed 2025-08-07.
- SEC Form 10-Q (accession 0001104506-25-000043): "•We initiated a Phase 2b study of brensocatib in patients with HS, which we refer to as the CEDAR trial, in December 2024." https://www.sec.gov/Archives/edgar/data/1104506/000110450625000043/insm-20250630.htm
- SEC Form 10-Q (accession 0001104506-25-000026): "•We initiated a Phase 2b study of brensocatib in patients with HS, which we refer to as the CEDAR trial, in December 2024." https://www.sec.gov/Archives/edgar/data/1104506/000110450625000026/insm-20250331.htm
- SEC Form 10-K (accession 0001104506-25-000009): "•We initiated a Phase 2b study of brensocatib in patients with HS, which we refer to as the CEDAR trial, in December 2024." https://www.sec.gov/Archives/edgar/data/1104506/000110450625000009/insm-20241231.htm

### Q1 2025: PDUFA date

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-05-08, last confirmed 2025-05-08.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-017858): "First-Quarter 2025 Highlights * Pending regulatory approval for bronchiectasis indication | FDA: Food and Drug Administration | PDUFA: Prescription Drug User Fee Act Mid- to late-stage programs refers to all clinical programs in Phase 2 and Phase 3 Double-digit ARIKAYCE growth All mid- to late-stage clinical programs on or ahead of schedule FDA review of brensocatib undisrupted PDUFA target action date of Aug. 12th for potential U.S. approval of brensocatib*" https://www.sec.gov/Archives/edgar/data/1104506/000114036125017858/ef20048527_ex99-2.htm

### February 6, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: bronchiectasis.
- First seen 2025-02-06, last confirmed 2025-10-30.
- SEC Form 10-Q (accession 0001104506-25-000053): "In February 2025, the FDA accepted our NDA, with priority review granted, for brensocatib in patients with bronchiectasis." https://www.sec.gov/Archives/edgar/data/1104506/000110450625000053/insm-20250930.htm
- SEC Form 10-Q (accession 0001104506-25-000043): "In February 2025, the FDA accepted our NDA, with priority review granted, for brensocatib in patients with bronchiectasis." https://www.sec.gov/Archives/edgar/data/1104506/000110450625000043/insm-20250630.htm
- SEC Form 10-Q (accession 0001104506-25-000026): "In February 2025, the FDA accepted our NDA, with priority review granted, for brensocatib in patients with bronchiectasis." https://www.sec.gov/Archives/edgar/data/1104506/000110450625000026/insm-20250331.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-029343): "In February 2025, the FDA accepted the Company's New Drug Application (NDA) for brensocatib for patients with bronchiectasis, granting the application Priority Review designation with a" https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-017858): "In February 2025, the FDA accepted the Company's New Drug Application (NDA) for brensocatib for patients with bronchiectasis, granting the application Priority Review designation with a Prescription" https://www.sec.gov/Archives/edgar/data/1104506/000114036125017858/ef20048527_ex99-1.htm
- SEC Form 8-K (accession 0001140361-25-003266): "On February 6, 2025, the Company issued a press release announcing that the FDA has accepted for review the Company's NDA for brensocatib for patients with non-cystic fibrosis bronchiectasis." https://www.sec.gov/Archives/edgar/data/1104506/000114036125003266/ef20043003_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-003266): "BRIDGEWATER, N.J., February 6, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for brensocatib for patients with non-cystic fibrosis bronchiectasis." https://www.sec.gov/Archives/edgar/data/1104506/000114036125003266/ef20043003_ex99-1.htm

### August 12, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat non-cystic fibrosis bronchiectasis.
- First seen 2025-08-12, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Brinsupri | brensocatib | 8/12/2025 | To treat non-cystic fibrosis bronchiectasisDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025
- openFDA Drugs@FDA: "NDA217673 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20250812, review_priority PRIORITY; sponsor_name INSMED INC; product BRINSUPRI (BRENSOCATIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217673%22
- Press release filed with the SEC (EX-99) (accession 0001140361-25-030537): "August 12, 2025 FDA Approval of BRINSUPRI™ for Patients with Non-Cystic Fibrosis" https://www.sec.gov/Archives/edgar/data/1104506/000114036125030537/ef20053490_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-039789): "In August 2025, the FDA approved the Company's New Drug Application (NDA) for brensocatib for patients with non-cystic fibrosis bronchiectasis (NCFB)." https://www.sec.gov/Archives/edgar/data/1104506/000114036125039789/ef20057768_ex99-1.htm
- SEC Form 8-K (accession 0001140361-25-030537): "On August 12, 2025, the Company announced that the FDA has approved BRINSUPRI (brensocatib 10 mg and 25 mg tablets), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis in adults and children 12 years and older." https://www.sec.gov/Archives/edgar/data/1104506/000114036125030537/ef20053490_8k.htm

### August 12, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact. Indication: Bronchiectasis Remains.
- First seen 2025-02-06, last confirmed 2025-08-07.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-005570): "The FDA had previously granted Priority Review to Insmed's NDA for brensocatib and set a target action date of August 12, 2025, under the Prescription" https://www.sec.gov/Archives/edgar/data/1104506/000114036125005570/ef20044166_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-005570): "—FDA Reaffirms Application is Under Priority Review with a PDUFA Target Action Date of August 12, 2025—" https://www.sec.gov/Archives/edgar/data/1104506/000114036125005570/ef20044166_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-029343): "—NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, 2025—" https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-017858): "—NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, 2025—" https://www.sec.gov/Archives/edgar/data/1104506/000114036125017858/ef20048527_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-005190): "—NDA for Brensocatib in Patients with Bronchiectasis Accepted by FDA and Granted Priority Review with a PDUFA Target Action Date of August 12, 2025—" https://www.sec.gov/Archives/edgar/data/1104506/000114036125005190/ef20043928_ex99-1.htm
- SEC Form 10-Q (accession 0001104506-25-000043): "Under the Prescription Drug User Fee Act (PDUFA), the FDA set a target action date of August 12, 2025." https://www.sec.gov/Archives/edgar/data/1104506/000110450625000043/insm-20250630.htm
- SEC Form 10-Q (accession 0001104506-25-000026): "Under the Prescription Drug User Fee Act (PDUFA), the FDA set a target action date of August 12, 2025." https://www.sec.gov/Archives/edgar/data/1104506/000110450625000026/insm-20250331.htm
- SEC Form 10-K (accession 0001104506-25-000009): "Under the Prescription Drug User Fee Act (PDUFA), the FDA set a target action date of August 12, 2025." https://www.sec.gov/Archives/edgar/data/1104506/000110450625000009/insm-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-005190): "Brensocatib in Bronchiectasis Accepted by FDA and Granted Priority Review with a PDUFA Target Action Date of August 12, 2025" https://www.sec.gov/Archives/edgar/data/1104506/000114036125005190/ef20043928_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-003266): "FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025" https://www.sec.gov/Archives/edgar/data/1104506/000114036125003266/ef20043003_ex99-1.htm
- FDA novel drug approvals: "Brinsupri | brensocatib | 8/12/2025 | To treat non-cystic fibrosis bronchiectasisDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025

### late 2025: topline data readout

- Status: delayed. Date confidence: half. Stage: 2. Indication: CRSsNP.
- First seen 2025-01-10, last confirmed 2025-08-07.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-005190): "Insmed continues to anticipate topline data from the study in the middle of 2025, ahead of the anticipated U.S. launch of brensocatib." https://www.sec.gov/Archives/edgar/data/1104506/000114036125005190/ef20043928_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-000711): "Topline data from the study are now anticipated in the middle of 2025, ahead of the anticipated U.S. launch of brensocatib." https://www.sec.gov/Archives/edgar/data/1104506/000114036125000711/ef20041296_ex99-1.htm
- SEC Form 10-Q (accession 0001104506-25-000026): "We anticipate reporting topline data from the BiRCh trial by the end of 2025." https://www.sec.gov/Archives/edgar/data/1104506/000110450625000026/insm-20250331.htm
- SEC Form 10-K (accession 0001104506-25-000009): "We anticipate reporting topline data from the BiRCh trial before the end of 2025." https://www.sec.gov/Archives/edgar/data/1104506/000110450625000009/insm-20241231.htm
- SEC Form 10-Q (accession 0001104506-25-000043): "•We completed enrollment in and anticipate topline data from the Phase 2b study of brensocatib in patients with CRSsNP, which we refer to as the BiRCh trial, by the end of 2025." https://www.sec.gov/Archives/edgar/data/1104506/000110450625000043/insm-20250630.htm
- SEC Form 10-Q (accession 0001104506-25-000026): "•We completed enrollment in and anticipate reporting topline data from the Phase 2b study of brensocatib in patients with CRSsNP, which we refer to as the BiRCh trial, by the end of 2025." https://www.sec.gov/Archives/edgar/data/1104506/000110450625000026/insm-20250331.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-029343): "—Topline Data Anticipated for Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP by the End of 2025—" https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-029343): "Insmed expects topline data from the Phase 2b BiRCh study of brensocatib in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) by the end of 2025." https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-017858): "—Enrollment Completed for Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP; Topline Data Anticipated By the End of 2025—" https://www.sec.gov/Archives/edgar/data/1104506/000114036125017858/ef20048527_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-005190): "The Phase 2b BiRCh study of brensocatib in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) remains on track to report topline results by the end of 2025." https://www.sec.gov/Archives/edgar/data/1104506/000114036125005190/ef20043928_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-029343): "Our teams continue to demonstrate executional excellence as we await the widely anticipated FDA approval and launch of brensocatib in bronchiectasis, advance our TPIP program in both PH-ILD and PAH, prepare for topline data from our Phase 2b BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps by the end of the year, and progress toward the read-out of our" https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_ex99-1.htm

### September 30, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Chronic Rhinosinusitis Without Nasal Polyps.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06013241 (A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor Insmed Incorporated." https://clinicaltrials.gov/study/NCT06013241

### Q4 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: pulmonary hypertension associated with interstitial lung disease.
- First seen 2025-10-30, last confirmed 2025-10-30.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-039789): "—PALM-ILD Phase 3 Study of TPIP for PH-ILD Expected to Initiate in the Fourth Quarter of 2025; Additional Phase 3 Studies Planned for PAH, PPF, and" https://www.sec.gov/Archives/edgar/data/1104506/000114036125039789/ef20057768_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-039789): "Insmed anticipates initiating PALM-ILD, a Phase 3 study of treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD), in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1104506/000114036125039789/ef20057768_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-039789): "Insmed plans to initiate a Phase 3 study of TPIP in patients with pulmonary arterial hypertension (PAH) in early 2026." https://www.sec.gov/Archives/edgar/data/1104506/000114036125039789/ef20057768_ex99-1.htm

### Jan 2026: topline data readout

- Status: delayed. Date confidence: month. Stage: 2. Indication: CRSsNP.
- First seen 2025-10-30, last confirmed 2025-10-30.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-039789): "—Topline Data Readout Anticipated for Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP by Early January 2026—" https://www.sec.gov/Archives/edgar/data/1104506/000114036125039789/ef20057768_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-039789): "Insmed expects to report topline data from the Phase 2b BiRCh study of brensocatib in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) by early January 2026." https://www.sec.gov/Archives/edgar/data/1104506/000114036125039789/ef20057768_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-039789): "—Phase 2b CEDAR Study of Brensocatib in Patients with HS Now Fully Enrolled, with Topline Data Anticipated in the First Half of 2026—" https://www.sec.gov/Archives/edgar/data/1104506/000114036125039789/ef20057768_ex99-1.htm
- SEC Form 10-Q (accession 0001104506-25-000053): "•We completed enrollment in and anticipate reporting topline data from the Phase 2b study of brensocatib in patients with CRSsNP, which we refer to as the BiRCh trial, by early January of 2026." https://www.sec.gov/Archives/edgar/data/1104506/000110450625000053/insm-20250930.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-039789): "Insmed now expects to report topline data from CEDAR in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1104506/000114036125039789/ef20057768_ex99-1.htm
- SEC Form 10-Q (accession 0001104506-25-000053): "We anticipate reporting topline data from the BiRCh trial by early January of 2026." https://www.sec.gov/Archives/edgar/data/1104506/000110450625000053/insm-20250930.htm
- SEC Form 10-Q (accession 0001104506-25-000053): "We anticipate topline data in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1104506/000110450625000053/insm-20250930.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-039789): "The Company anticipates the topline readout of the Phase 3 ENCORE trial in the first half of 2026 in patients with newly diagnosed or recurrent Mycobacterium avium complex (MAC) lung disease who have not started antibiotics." https://www.sec.gov/Archives/edgar/data/1104506/000114036125039789/ef20057768_ex99-1.htm

### February 12, 2026: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 2. Indication: Hidradenitis Suppurativa.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06685835 (A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-02-12 (ACTUAL); Lead Sponsor Insmed Incorporated." https://clinicaltrials.gov/study/NCT06685835

### Q2 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: HS Now.
- First seen 2026-01-09, last confirmed 2026-02-19.
- Press release filed with the SEC (EX-99) (accession 0001140361-26-006116): "Insmed anticipates reporting topline data from CEDAR in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1104506/000114036126006116/ef20066055_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-000778): "Insmed anticipates reporting topline data from CEDAR in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1104506/000114036126000778/ef20062540_ex99-1.htm
- SEC Form 10-K (accession 0001104506-26-000009): "We anticipate reporting topline data in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1104506/000110450626000009/insm-20251231.htm
- SEC Form 10-K (accession 0001104506-26-000009): "CEDAR is fully enrolled, and we anticipate reporting topline data in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1104506/000110450626000009/insm-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-000778): "— Topline Data from Phase 2b CEDAR Study of Brensocatib in Patients with HS Now Anticipated in the Second Quarter of 2026—" https://www.sec.gov/Archives/edgar/data/1104506/000114036126000778/ef20062540_ex99-1.htm

### 2H 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-10-30, last confirmed 2025-10-30.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-039789): "The Company anticipates initiating additional Phase 3 studies of TPIP in progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF) in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1104506/000114036125039789/ef20057768_ex99-1.htm

## Same indication

- [Avtx-009 regimen 1](https://sec-api.dev/pdufa/avtx-009-regimen-1) (AVTX)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [Eltrekibart](https://sec-api.dev/pdufa/eltrekibart) (LLY)
- [Lutikizumab](https://sec-api.dev/pdufa/lutikizumab) (ABBV)
- [Olatorepatide](https://sec-api.dev/pdufa/olatorepatide) (REGN)
- [Rhapsido® (remibrutinib)](https://sec-api.dev/pdufa/remibrutinib) (NVS)
- [Litfulo (ritlecitinib tosylate)](https://sec-api.dev/pdufa/ritlecitinib) (PFE)
- [Ruxolitinib cream](https://sec-api.dev/pdufa/ruxolitinib-cream) (INCY)
- [Sar444656 (kt-474)](https://sec-api.dev/pdufa/sar444656-kt-474) (SNY)
- [SAR445399](https://sec-api.dev/pdufa/sar445399) (SNY)
- [Sonelokimab](https://sec-api.dev/pdufa/sonelokimab) (MLTX)
- [Tulisokibart](https://sec-api.dev/pdufa/tulisokibart) (MRK)
- [Zasocitinib (dose a)](https://sec-api.dev/pdufa/zasocitinib-dose-a) (TAK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/brensocatib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "BRINSUPRI® (brensocatib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/brensocatib

```bibtex
@misc{secapidev_pdufa_brensocatib_20261116,
  title        = {BRINSUPRI® (brensocatib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/brensocatib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_brensocatib_20261116","title":"BRINSUPRI® (brensocatib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/brensocatib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
